Daiichi Sankyo and Sarah Cannon Research Institute announced that extended follow-up data from a phase 1/2 trial of DS-7300, a specifically designed potential first-in-class B7-H3 directed DXd antibody drug conjugate, continues to show promising durable tumor response in patients with several types of heavily pretreated cancers including lung, prostate or esophageal cancer.
September 10, 2022
· 11 min read